$7 M

CTRV Mkt cap, 12-Dec-2018
ContraVir Pharmaceuticals Net income (Q3, 2018)-157.1 K
ContraVir Pharmaceuticals EBIT (Q3, 2018)-3.9 M
ContraVir Pharmaceuticals Cash, 30-Sep-20189 M

ContraVir Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

314.2k8.4m15.0m13.7m

General and administrative expense

1.4m5.6m5.8m7.4m

Operating expense total

1.7m14.0m20.8m21.0m

EBIT

(1.7m)(14.0m)(20.8m)(21.0m)

Interest expense

12.9k

Pre tax profit

(16.8m)

Income tax expense

1.9m

Net Income

(5.3m)(14.3m)(17.0m)(14.9m)

Quarterly

USDQ1, 2014Q2, 2014Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018

R&D expense

13.6k9.2k3.8m4.0m3.1m4.3m2.9m4.0m2.3m2.1m2.2m

General and administrative expense

166.7k154.1k1.1m1.5m1.7m1.7m2.0m1.9m1.6m1.8m1.7m

Operating expense total

180.4k163.3k4.8m5.5m4.9m6.0m4.9m5.8m3.9m7.7m3.9m

Depreciation and amortization

6.0k

EBIT

(180.4k)(163.3k)(4.8m)(5.5m)(4.9m)(6.0m)(4.9m)(5.8m)(3.9m)(3.9m)(3.9m)

Interest expense

1.7k4.9k231.9k55.5k

Pre tax profit

(6.4m)(7.6m)(3.2m)(4.0m)(157.1k)

Income tax expense

1.9m1.9m536.0k536.0k

Net Income

(182.1k)(168.2k)(4.8m)(3.0m)(4.8m)(4.5m)(7.6m)(5.8m)(2.7m)(4.0m)(157.1k)

ContraVir Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.8m4.6m7.4m6.0m

Accounts Receivable

Inventories

Current Assets

2.0m5.2m7.9m6.1m

PP&E

14.5k81.4k80.8k56.6k

Goodwill

1.9m1.9m

Total Assets

2.0m5.4m13.1m11.3m

Accounts Payable

243.9k1.5m4.3m1.6m

Short-term debt

Current Liabilities

458.7k1.9m5.1m2.6m

Long-term debt

Total Debt

Total Liabilities

4.9m1.9m11.8m7.5m

Additional Paid-in Capital

2.5m17.4m32.2m69.7m

Retained Earnings

(5.4m)(27.6m)(44.6m)(67.0m)

Total Equity

(2.9m)3.4m1.3m3.7m

Financial Leverage

-0.7 x1.6 x9.9 x3 x

ContraVir Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.3m)(14.3m)(17.0m)(14.9m)

Depreciation and Amortization

1.3k16.4k21.5k28.0k

Accounts Receivable

Inventories

Accounts Payable

3.1m(2.1m)

Cash From Operating Activities

(1.4m)(9.7m)(16.6m)(19.2m)

Purchases of PP&E

(15.8k)(83.3k)(6.6k)(14.7k)

Cash From Investing Activities

(15.8k)(83.3k)(502.2k)(14.7k)

Cash From Financing Activities

3.1m12.5m19.9m24.8m

Interest Paid

12.9k12.9k

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018

Net Income

(4.8m)(3.0m)(4.8m)(4.5m)(16.9m)(5.8m)(2.7m)

Depreciation and Amortization

7.1k13.1k21.5k6.0k4.9k14.1k

Accounts Payable

213.3k114.4k1.3m3.2m3.2m3.4m4.4m(1.8m)(2.6m)146.0k655.7k

Cash From Operating Activities

(4.4m)(9.7m)(14.9m)(5.4m)(3.6m)(7.0m)(10.6m)

Purchases of PP&E

(12.3k)(12.3k)

Cash From Investing Activities

(12.3k)(12.3k)900.0900.0900.0

Cash From Financing Activities

2.2k12.9m13.7m1.2m1.6m3.6m13.6m

ContraVir Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

3.1 x
Report incorrect company information